Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma

Leukemia Research

Volumn 31, Issue 5, 2007, Pages 721-723

  Mele, Giuseppe ^a   Pinna, Salvatore ^a   Alloro, Emilia ^a   Brocca, Maurizio Claudio ^a   Coppi, Maria Rosaria ^a   Quarta, Giovanni ^a  

^a PERRINO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

ADULT; BONE MARROW BIOPSY; CANCER REGRESSION; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; HUMAN; LETTER; MALE; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; PELVIS TUMOR; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BRAIN NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PYRAZINES; TREATMENT FAILURE;

EID: 34147163315     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.06.019     Document Type: Letter

References (8)

1. Patriarca F., Prosdocimo S., Tomadini V., et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematol/Hematol J 90 2 (2005) 278-279
2. Krauth M.T., Bankier A., Valent P., et al. Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. Leuk Res 29 (2005) 1473-1477
3. Adams J., Palombella V.J., and Elliott P.J. Proteasome inhibition: a new strategy in cancer treatment. Investig New Drugs 18 (2000) 109-121
4. Supko J.G., Eder J.P., Lynch T.J., et al. Pharmacokinetics of irinotecan and the proteasome inhibitor bortezomib in adult patients with solid malignancies. Proc Am Soc Clin Oncol 22 (2003) 136 [Abs 544]
5. Schwartz R., and Davidson T. Pharmacology, pharmacokinetics and practical applications of bortezomib. Oncology (Williston Park) 18 14 Suppl. 11 (2004) 14-21
6. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59 (1999) 2615-2622
7. Adams J., and Kauffman M. Development of the proteasome inhibitor velcade (bortezomib). Cancer Invest 22 (2004) 304-311
8. Kropff M.H., Bisping G., Wenning D., et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Blood 104 11 (2004) 4923 [Abs]